11 – 15 February 2017 Mon, 13 February
Davos 2
08:00 – 09:30 Session 1: Lipid Management / Diabetes
Chairs: S. Sharma, London and F. Mach, Geneva
08:00 The ESC/EAS Guidelines for detection and treatment of dyslipidemias: What is new? A. L. Catapano, Milan
08:22 Triglycerides on the rise – addressing residual lipid risk in the era of profound LDL reduction P. Libby, Boston
08:44 Interfaces of diabetes with cardiovascular disease M. A. Pfeffer, Boston
09:06 Guideline-based treatment of type 2 diabetes R. Lehmann, Zurich
09:30 – 10:00 Coffee

Davos 2
10:00 – 11:30 Session 2: Acute Coronary Syndromes
Chairs: W. Wijns, Galway and S. Windecker, Berne
10:00 Coronary microvascular dysfunction: an update F. Crea, Rome
10:22 New ESC Guidelines on NSTEMI C. Müller, Basel
10:44 Duration of DAPT after stenting: towards an individualized therapy T. F. Lüscher, Zurich
11:06 Takotsubo, an often unrecognized acute heart disease J. R. Ghadri, Zurich
12:00 – 13:15 Lunch / Satellite Symposium Boehringer Ingelheim (a lunch bag will be offered)
Chair: B. Meier, Berne

Mind the gap – Close the gap

12:00 Introduction B. Meier, Berne
12:05 Heart failure in diabetes type 2: When evidence generates hypothesis F. Ruschitzka, Zurich
12:35 Cardiac emergencies: The missing pieces of the puzzle? C. Müller, Basel
13:05 Discussion and take-home message B. Meier, Berne
12:00 – 13:15 Lunch / Satellite Symposium Bristol-Myers Squibb / Pfizer (a lunch bag will be offered)
Chairs: J. Steffel, Zurich and F. Mach, Geneva

Anticoagulation in routine clinical use – an interactive patient-centred symposium


12:00 Introduction F. Mach, Geneva
12:05 Apixaban in daily clinical practice A. Breitenstein, Zurich
12:25 Anticoagulation in renal insufficiency – What is the evidence? J. Steffel, Zurich
12:45 Challenging situations – interactive case discussion F. Mach, Geneva
13:10 Take-home message J. Steffel, Zurich
Davos 2
13:30 – 15:00 Session 3: Stable Coronary Artery Disease
Chairs: B. Meier, Berne and C. Müller, Basel
13:30 Challenging PCIs: main stem and bifurcation lesions W. Wijns, Galway
13:52 CTO: a new window for PCI O. Gämperli, Zurich
14:14 Debate - From SYNTAX to FREEDOM and STICH: PCI is moving to center stage S. Windecker, Berne
14:36 Debate - From SYNTAX to FREEDOM and STICH: ACBP is still my first choice F. Maisano, Zurich
15:00 – 15:30 Coffee

15:00 – 16:30 Poster Session: Arrhythmias, Angina and Revascularisation
Chair: G. S. Pitt, New York
15:30 – 16:30 Meet the Expert Session - Diabetes management: How to improve outcomes
Moderators: M. A. Pfeffer, Boston and R. Lehmann, Zurich
Cases: J. Stehli, Zurich and G. Anand, Zurich
15:30 – 16:30 Meet the Expert Session - Guideline-based management of dyslipidemias
Moderators: A. L. Catapano, Milan and F. Mach, Geneva
Cases: I. Sudano, Zurich and B. Gencer, Geneva
15:30 – 16:30 Meet the Expert Session - Should we treat every angiographic relevant stenosis? Importance of hemodynamic measurements
Moderator: W. Wijns, Galway
Cases: K. Weber, Winterthur and O. Gämperli, Zurich
Davos 1
15:30 – 16:30 Symposium - Myocardial Infarction in Switzerland: Results from the SPUM Registry
Chairs: S. Windecker, Berne and T. F. Lüscher, Zurich
15:30 Characteristics of patients with MI in Switzerland C. M. Matter, Zurich
15:50 Quality of secondary prevention after acute MI F. Mach, Geneva
16:10 Outcome S. Obeid, Zurich
Davos 2
16:30 – 17:30 Session 4: Ventricular Arrhythmias
Chairs: P. Elliott, London and C. Brunckhorst, Zurich
16:30 ESC Guidelines on ventricular arrhythmias and SCD A. J. Camm, London
16:50 Ion channels and arrhythmias G. S. Pitt, New York
17:10 Management of ventricular tachycardias H. Calkins, Baltimore
Davos 1
16:30 – 17:30 Session 5: Structural Interventions
Chairs: W. Maier, Zurich and F. Maisano, Zurich
16:30 Debate: LAA closure as a first-line therapy in AF patients: pro F. Nietlispach, Zurich
16:45 Debate: LAA closure as a first-line therapy in AF patients: contra J. Steffel, Zurich
17:00 Debate: PFO closure after publication of 3 randomized trials: pro B. Meier, Berne
17:15 Debate: PFO closure after publication of 3 randomized trials: contra K. Nedeltchev, Aarau
17:30 – 18:00 Apéro Riche

only for participants of the satellite symposium

Davos 2
18:00 – 19:15 Satellite Symposium Amgen
Chair: T. F. Lüscher, Zurich

Lipid management with the PCSK9 inhibitor evolocumab: Update and first evidence of clinical outcomes

18:00 Introduction T. F. Lüscher, Zurich
18:05 LDL management: How low can you go? The PROFICIO Study program A. L. Catapano, Milan
18:25 Results from the GLAGOV trial: Managing plaque burden K. Koskinas, Berne
18:45 Evolocumab in clinical practice: Selected case reports I. Sudano, Zurich
19:05 Discussion and take-home message T. F. Lüscher, Zurich
19:20 – 20:15 Clinical Seminar - Difficult ECG Interpretations
Panel: C. Brunckhorst, Zurich and F. Duru, Zurich
19:20 – 20:15 Clinical Seminar - Echo Pearls / Advanced Echo Imaging
Panel: M. Zuber, Zurich and F. C. Tanner, Zurich